Elevian's Launch to Develop Medicines for Longevity and Age-Related Disorders
Shots:
- Elevian generated a seed funding of $5.5M from investors including WTI- Stanford StartX- Longevity Fund- Kizoo Ventures- Thynk Capital among others
- Its founders focus on regenerative effects of young blood and identified a specific circulating factor GDF11- by experimenting circulatory systems of young and old mice and observed regeneration of many tissues and organs in the old mice after 30 days
- GDF11 (a growth differentiation factor 11) reduces age-related cardiac hypertrophy- accelerates skeletal muscle repair- improves exercise capacity and brain function. Elevian will focus on is CAD- Alzheimer disease- T2D and sarcopenia- an age-related muscle dysfunction disorder
Ref: Elevian | Image: Elevian
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com